Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Registration fees
Hotel
Venue
Eco-friendly info
Programme
Abstract Submission
Postgraduate Teaching
Nurse Programme
Hands-on
Industry Programme
Acknowledgements
CME Accreditation
UEG Week on-demand
Congress Resources
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Projects
Research Prize
Research Fellowship
Research Webinars
Advocacy
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
Guideline development framework
Guideline development course
Get Funding
Get Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Application Support
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Session
IBD (Posters)
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
E- CONSULTS IN INFLAMMATORY BOWEL DISEASE (TELEIBD): FACILITATING COMMUNICATION BETWEEN SPECIALIZED AND PRIMARY CARE
DECODING THE TAXONOMIC AND FUNCTIONAL PROFILES OF MICROBIOTA IN INFLAMMATORY BOWEL DISEASES–A MULTI-OMICS APPROACH
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
IFN-GAMMA-TREATED MACROPHAGES INDUCE EMT THROUGH THE WNT PATHWAY: RELEVANCE IN CROHN´S DISEASE
SUBCLINICAL INFLAMMATORY BOWEL DISEASE PRECEDES THE DIAGNOSIS AND LEADS TO AN INCREASE IN HEALTHCARE RESOURCES UTILIZATION: MULTICENTER CASE-CONTROL STUDY
PREVALENCE AND CLINICAL FACTORS ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
THE OVERLAP BETWEEN CANNABINOID AND NOCICEPTIN SIGNALING AND ITS ROLE IN INTESTINAL INFLAMMATION – A PILOT STUDY
TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE
HIGH C-REACTIVE PROTEIN LEVEL OF ACUTE SEVERE ULCERATIVE COLITIS IS ASSOCIATED WITH RE-ADMISSION DUE TO AGGRAVATION OF ULCERATIVE COLITIS: A KASID MULTICENTER STUDY
COMBINATION THERAPY IS NOT ASSOCIATED WITH IMPROVED RATES OF CLINICAL OR ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH USTEKINUMAB OR VEDOLIZUMAB
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM
IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
EFFECT OF TRANSITION CARE ON CLINICAL OUTCOMES AND TREATMENT ADHERENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL PROSPECTIVE STUDY
EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT
Item 241 - 260 / 612
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Chat with us
, powered by
LiveChat